- Home
- PFLT vs IMTX Comparison
PFLT vs IMTX Comparison
Compare PFLT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- IMTX
- Stock Information
- Founded
- PFLT 2010
- IMTX N/A
- Country
- PFLT United States
- IMTX Germany
- Employees
- PFLT N/A
- IMTX N/A
- Industry
- PFLT Finance: Consumer Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFLT Finance
- IMTX Health Care
- Exchange
- PFLT Nasdaq
- IMTX Nasdaq
- Market Cap
- PFLT 1.0B
- IMTX 865.5M
- IPO Year
- PFLT N/A
- IMTX N/A
- Fundamental
- Price
- PFLT $9.20
- IMTX $10.48
- Analyst Decision
- PFLT Buy
- IMTX Strong Buy
- Analyst Count
- PFLT 6
- IMTX 4
- Target Price
- PFLT $10.75
- IMTX $13.67
- AVG Volume (30 Days)
- PFLT 1.6M
- IMTX 1.2M
- Earning Date
- PFLT 11-24-2025
- IMTX 11-17-2025
- Dividend Yield
- PFLT 13.56%
- IMTX N/A
- EPS Growth
- PFLT N/A
- IMTX N/A
- EPS
- PFLT 0.81
- IMTX N/A
- Revenue
- PFLT $247,973,000.00
- IMTX $152,823,253.00
- Revenue This Year
- PFLT $42.15
- IMTX N/A
- Revenue Next Year
- PFLT $11.75
- IMTX $13.53
- P/E Ratio
- PFLT $11.16
- IMTX N/A
- Revenue Growth
- PFLT 48.88
- IMTX 83.61
- 52 Week Low
- PFLT $8.40
- IMTX $3.30
- 52 Week High
- PFLT $11.63
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- PFLT 55.00
- IMTX 63.59
- Support Level
- PFLT $8.40
- IMTX $9.99
- Resistance Level
- PFLT $8.90
- IMTX $11.07
- Average True Range (ATR)
- PFLT 0.18
- IMTX 0.64
- MACD
- PFLT 0.10
- IMTX -0.12
- Stochastic Oscillator
- PFLT 100.00
- IMTX 59.95
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.